KBCK Trial: Pioneering Kinder Cancer Treatments

The Killing Breast Cancer Kindly (KBCK) trial is a groundbreaking international, multi-center initiative designed to redefine the approach to breast cancer treatment. The trial focuses on providing personalized, kinder, and more effective options for curing early-stage breast cancer by leveraging cutting-edge technology.

By collaborating with DIGI UK, an innovator in medical technology, we aim to make cancer treatment less invasive and more accessible while preserving the efficacy of care. This initiative embodies our commitment to reducing the physical, emotional, and financial toll that cancer treatments can impose on patients.

In partnership with DIGI UK, we are introducing the Digistain prognostic test, a revolutionary tool that evaluates the aggressiveness of breast cancer tumors. This advanced mid-infrared imaging technology measures the ratio of nuclear-to-cytoplasmic chemicals in tissue cells, generating the Digistain Index (DI). This index:

• Accurately identifies tumor aggressiveness: Differentiates between highly aggressive and less aggressive breast cancer tumors.
• Enables personalized treatment: Allows for the use of hormone therapy to treat less aggressive tumors, reducing the need for chemotherapy and its associated risks.
• Delivers rapid results: Provides instant prognostic data, eliminating delays caused by overseas testing.
• Improves affordability and accessibility: Offers a cost-effective alternative to expensive genomic diagnostic tests.

With its ability to deliver precise prognostic data at a fraction of the cost, Digistain empowers oncologists to make informed, timely decisions, ensuring better patient outcomes while minimizing unnecessary treatments.

Learn more about Digistain and their innovative technology by visiting their website at digistain.co.uk.

• Title: Killing Breast Cancer Kindly (KBCK)
• Objective: Optimal personalized treatment for early breast cancer using the Digistain technology.
• Technology: Digistain evaluates aneuploidy (cell abnormality) and produces a reliable prognostic index (DI).
• Study Design:
  • Compares patient management using the Digistain test-directed approach with standard chemotherapy protocols.
  • Includes a preliminary phase (KBCK Prelim) to assess large-scale trial feasibility and confirm the technology.

In a landmark study involving 801 early breast cancer patients, Digistain demonstrated exceptional accuracy in predicting patient outcomes, categorizing individuals into high-risk or low-risk groups. This innovation promises to substantially reduce unnecessary chemotherapy treatments, enhancing the quality of care while significantly lowering costs.

1. Empowering Cancer Patients: The trial emphasizes personalized care by providing treatment options tailored to the aggressiveness of the tumor.
2. Advancing Accessibility: By offering a cost-effective alternative to overseas diagnostic tests, we are making lifesaving cancer treatments accessible to a broader population.
3. Reducing Treatment Risks: By avoiding unnecessary chemotherapy for low-risk patients, the trial minimizes the complications and side effects associated with aggressive treatments.
4. Promoting Awareness: Our broader mission includes creating awareness about cancer prevention, treatment, and cure. By educating communities, especially young individuals, about the importance of early detection and tailored care, we aim to inspire a proactive approach to health.

At Killing Cancer Kindly, we envision a world where cancer treatment is as gentle as it is effective. The KBCK trial represents a significant step toward achieving that goal.

We invite you to support this innovative research, whether by spreading awareness, donating to our cause, or partnering with us in our mission. Together, we can make a meaningful difference in the lives of countless patients around the globe.